Document is current
Any future updates will be listed below
-
Authors
Brasu, Nadia https://orcid.org/0000-0001-7008-3727
Elia, Ines
Russo, Valentina
Montacchiesi, Gaia
Stabile, Simona Aversano
De Intinis, Carlo https://orcid.org/0000-0002-6791-7126
Fesi, Francesco
Gizzi, Katiuscia
Macagno, Marco https://orcid.org/0000-0002-1749-7813
Montone, Monica
Mussolin, Benedetta
Grifoni, Alba https://orcid.org/0000-0002-2209-5966
Faravelli, Silvia
Marchese, Silvia https://orcid.org/0000-0003-3822-7174
Forneris, Federico https://orcid.org/0000-0002-7818-1804
De Francesco, Raffaele https://orcid.org/0000-0001-8754-5123
Sette, Alessandro https://orcid.org/0000-0001-7013-2250
Barnaba, Vincenzo https://orcid.org/0000-0001-7908-8049
Sottile, Antonino
Sapino, Anna https://orcid.org/0000-0003-3542-9571
Pace, Luigia https://orcid.org/0000-0002-1694-2401
-
Funding
Funding for this research was provided by:
Giovanni Armenise-Harvard Foundation (CDA)
Ministero della Salute (COVID-2020-12371849, Ricerca Corrente 2021, Ricerca Corrente)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (No. 75N93021C00016)
- License Information
-
More Information
Article History
Received: 18 January 2022
Accepted: 10 August 2022
First Online: 22 September 2022
Competing interests
: A.Sette is a consultant for Gritstone Bio, Flow Pharma, Arcturus Therapeutics, ImmunoScape, CellCarta, Avalia, Moderna, Fortress and Repertoire. All other authors declare no conflicts of interest. L.J.I. has filed for patent protection for various aspects of T cell epitope and vaccine design work. CCI. has filed a patent for immune correlate of protection after RNA vaccination. R.D.F. is a consultant for Moderna Inc. The data are tabulated in the main paper and in the supplementary materials.
Free to read: This content has been made available to all.
